Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 pm CET/8:30 am ET. Calliditas will also host 1×1 meetings during the conference. Details for the presentation are as follows:
Jefferies Virtual Healthcare Conference
Date: Tuesday, June 1, 2021
Time: 2:30 pm CET / 8:30 am ET
The webcast will be archived for a period of 30 days following the conclusion of the event.
For further information, please contact:
Marie Galay, IR Manager, Calliditas
The information was sent for publication, through the agency of the contact persons set out above, on May 28, 2021 at 12:00 p.m. CET.
Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas’ lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas successfully reported top line data of its global Phase 3 study in IgAN in November of 2020 and, if approved, aims to commercialize Nefecon in the United States on its own and partner elsewhere. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.